Celldex Therapeutics CLDX Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $1.55M-78.0% | $7.02M+2.0% | $6.88M+192% | $2.36M-49.3% | ||
| $245.07M+49.8% | $163.55M+38.6% | $118.01M+43.5% | $82.26M+54.3% | ||
| $43.84M+13.7% | $38.55M+24.7% | $30.91M+13.7% | $27.2M+32.7% | ||
| $288.91M+43.0% | $202.1M+25.2% | $161.43M+37.3% | $117.59M+54.9% | ||
| -$287.37M-47.3% | -$195.08M-26.2% | -$154.54M-34.1% | -$115.23M-61.7% | ||
| -18,587.7%-15,809pp | -2,778.9%-534pp | -2,245.3%+2,644pp | -4,889%-3,358pp | ||
| -$258.76M-63.9% | -$157.86M-11.6% | -$141.43M-25.9% | -$112.33M-59.3% | ||
| -16,737.2%-14,488pp | -2,248.8%-194pp | -2,054.8%+2,711pp | -4,765.6%-3,250pp | ||
| -$3.90-59.2% | -$2.45+16.1% | -$2.92-21.7% | -$2.40-46.3% | ||
| -$283.99M-48.0% | -$191.9M-26.6% | -$151.53M-34.9% | -$112.34M-64.8% | ||
| -18,369.1%-15,635pp | -2,733.6%-532pp | -2,201.6%+2,565pp | -4,766.1%-3,301pp | ||
| -$287.37M-47.3% | -$195.08M-26.2% | -$154.54M-34.1% | -$115.23M-61.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Celldex Therapeutics's revenue?
- Celldex Therapeutics (CLDX) generated $866.0K in revenue over the trailing twelve months, down 88.5% year over year.
- Is Celldex Therapeutics profitable?
- Celldex Therapeutics is not currently profitable: it reported a net loss of $283.6M over the trailing twelve months, a -32753.6% net margin.
- What is Celldex Therapeutics's earnings per share?
- Celldex Therapeutics's diluted EPS over the trailing twelve months is $-4.27.
- Where does Celldex Therapeutics's income statement data come from?
- Every line is extracted from Celldex Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
